ArticleFluids and barriers of the CNS2026
Plasma p-Tau217 and amyloid-β oligomers as complementary biomarkers for differential diagnosis, comorbidity detection and disease monitoring in idiopathic normal pressure hydrocephalus.
Article in Fluids and barriers of the CNS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundIdiopathic normal pressure hydrocephalus (iNPH) overlaps clinically and pathologically with Alzheimer’s disease (AD), making differential diagnosis and prognostication challenging. The identification of reliable and minimally invasive plasma biomarkers would have major clinical implications for distinguishing iNPH from AD and for monitoring disease course and surgical outcomes.
methodsWe conducted three studies: (Study 1) cross‑sectional comparisons of plasma phosphorylated tau 217 (p‑Tau217) and amyloid-β oligomers (AβO) among healthy controls (HCs; n = 22), iNPH (n = 76), and AD (n = 23) groups, accompanied by receiver operating characteristic (ROC) analysis; (Study 2) correlation analyses within preoperative iNPH group to assess associations between biomarkers and clinical indices, as well as two‑group comparisons between iNPH group with and without AD pathology stratified by CSF p‑Tau181 > 30 pg/mL; and (Study 3) longitudinal pre- and postoperative assessments following shunt surgery.
resultsIn the three‑group analyses, plasma p‑Tau217 effectively discriminated iNPH from AD (AUC = 0.79, 95% = CI 0.700–0.882), whereas discrimination between HCs and iNPH was poor (AUC = 0.48). Plasma AβO moderately discriminated HCs from iNPH (AUC = 0.71, 95% CI = 0.567–0.848). In the preoperative iNPH group, CSF and plasma p‑Tau217 showed a strong correlation (ρ = 0.736, p < 0.001), whereas CSF and plasma AβO showed no significant correlation (ρ = −0.047, p = 0.689). Among iNPH group with AD pathology (CSF p-Tau181 > 30 pg/mL), plasma p-Tau217 was higher, plasma AβO was lower, and Frontal Assessment Battery (FAB) scores were reduced compared with those without AD pathology. For detecting coexistent AD pathology in iNPH group, AUCs were modest for plasma p‑Tau217 (0.64), AβO (0.63), and p‑Tau217/AβO ratio (0.66). Postoperatively, iNPH grading scale (GS), Mini-Mental State Examination (MMSE), and FAB scores improved significantly; CSF and plasma AβO levels decreased, CSF p‑Tau217 increased, whereas plasma p‑Tau217 levels remained stable.
conclusionsPlasma p-Tau217, reflecting AD-related pathology, and plasm AβO, reflecting disease stage, provide complementary information for distinguishing iNPH from AD, assessing comorbidity of AD pathology in iNPH and evaluating postoperative changes. Their combined measurement may support differential diagnosis, aid the preoperative identification of concomitant AD pathology in iNPH, and serve as a minimally invasive screening and triage tool as well as a means of postoperative monitoring, while acknowledging that discrimination between HCs and iNPH at individual level remains limited.
trial registrationNot applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.